Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex ...

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based ...

Acer Aspire VX-15 is a Windows 10 Home laptop with a 15.60-inch display that has a resolution of 1920x1080 pixels. It is powered by a Core i7 processor and it comes with 8GB of RAM. The Acer Aspire VX ...

This dual-band CDMA camera phone sports a large 262,000-color main display, OLED outer display, voice dialing, voice memo, BREW (Get It Now), and 1xRTT high-speed data.